SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities-Reference-Cited by-同舟云学术

SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities

Published:2021-04-01 Issue:7 Volume:131 Page:
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Casadevall Arturo^ORCID,Henderson Jeffrey P.,Joyner Michael J.,Pirofski Liise-anne

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/148832/files/pdf

Reference16 articles.

1. Cortez MF. Chronic Covid-19 and convalescent plasma may boost mutation risk. Bloomberg. February 6, 2021. Accessed February 24, 2021. https://www.bloombergquint.com/onweb/chronic-covid-19-and-convalescent-plasma-may-boost-mutation-risk

2. Walker M. Did convalescent plasma for COVID-19 unleash viral mutation? MedpageToday. February 5, 2021. Accessed February 24, 2021. https://www.medpagetoday.com/infectiousdisease/covid19/91088

3. SARS-CoV-2 evolution during treatment of chronic infection;Kemp;Nature

4. Andreano E, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma [preprint]. https://doi.org/10.1101/2020.12.28.424451 Posted on on bioRxiv December 28, 2020

5. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant;Yurkovetskiy;Cell,2020

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single Monoclonal Antibodies Should Not Be Used for Coronavirus Disease 2019 Therapy: A Call for Antiviral Stewardship;Clinical Infectious Diseases;2024-08-08

2. Utility of COVID-19 Seropositive Plasma as Convalescent Plasma: An Immune and Neutralization Antibody Seroprevalence Analysis in Blood Donors for Future Potential Pandemic Readiness;Cureus;2024-03-28

3. Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab);Microbiology Spectrum;2023-12-12

4. Cooperative and structural relationships of the trimeric Spike with infectivity and antibody escape of the strains Delta (B.1.617.2) and Omicron (BA.2, BA.5, and BQ.1);Journal of Computer-Aided Molecular Design;2023-10-04

5. Re-Emerging COVID-19: Controversy of Its Zoonotic Origin, Risks of Severity of Reinfection and Management;International Journal of General Medicine;2023-09